Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer

Thyroid ◽  
2020 ◽  
Vol 30 (10) ◽  
pp. 1458-1469 ◽  
Author(s):  
Christopher A. Muir ◽  
Alexander M. Menzies ◽  
Roderick Clifton-Bligh ◽  
Venessa H.M. Tsang
Keyword(s):  
Advanced Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Treatment ◽  
Thyroid Toxicity

scholarly journals Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer

2021 ◽  
Vol 10 (1) ◽  
pp. 1929727
Author(s):  
Bao-Dong Qin ◽  
Xiao-Dong Jiao ◽  
Xin-Cheng Zhou ◽  
Bin Shi ◽  
Jian Wang ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Advanced Cancer ◽  
Proton Pump ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

2017 ◽  
Vol 76 (10) ◽  
pp. 1747-1750 ◽  
Author(s):  
Rakiba Belkhir ◽  
Sébastien Le Burel ◽  
Laetitia Dunogeant ◽  
Aurélien Marabelle ◽  
Antoine Hollebecque ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Immune Checkpoint ◽  
Polymyalgia Rheumatica ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Treatment

Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors

Immunotherapy ◽  
2021 ◽  
Author(s):  
Adi Kartolo ◽  
Cynthia Yeung ◽  
Gordon T Moffat ◽  
Lilian Hanna ◽  
Wilma Hopman ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Advanced Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Single Agent ◽  
Cancer Management ◽  
Thromboembolism Events

Aim: To evaluate the correlation between venous thromboembolism events (VTEs) and immune checkpoint inhibitor (ICI)-based regimens. Methods: This is a retrospective study of 403 patients with advanced cancer on ICI-based regimens. Results: We report 8% VTE incidence post-ICI initiation over a median of 11.1 months of follow-up. Compared with single-agent ICI, dual-ICI was significantly correlated with higher incidence of VTE (odds ratio [OR]: 4.196, 95% CI: 1.527–11.529, p = 0.005), but chemotherapy–immuno-oncology combination was not (OR: 1.374, 95% CI: 0.285–6.632, p = 0.693). Subsequent systemic therapy post-ICI was also independently associated with higher VTE incidence (OR: 2.599, 95% CI: 1.169–5.777, p = 0.019). Conclusion: Our findings suggest potential underreporting of VTE incidence in ICI clinical trials. As dual-ICI is becoming more prevalent in cancer management, clinicians should maintain vigilance regarding VTE in patients with advanced cancer on ICI-based regimens.

“Restlessness” After Cancer Diagnosis and Treatment

2021 ◽  
pp. 157-159
Author(s):  
Anastasia Zekeridou
Keyword(s):  
Cerebrospinal Fluid ◽  
Cancer Diagnosis ◽  
Immunoglobulin G ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Hyperkinetic Movement Disorder ◽  
Phosphodiesterase 10A ◽  
Cancer Remission ◽  
Inhibitor Treatment

A 76-year-old woman sought care for unintentional weight loss, hematuria, and fatigue. She was diagnosed with plurimetastatic renal cell carcinoma. After resection of the primary tumor and metastases, she was treated with pembrolizumab, an immune checkpoint inhibitor. The patient experienced involuntary tongue and face movements with dysphagia and weight loss. She was also described as “restless.” At that point, the patient was in cancer remission with ongoing immune checkpoint inhibitor treatment. Blood testing was unremarkable. Brain magnetic resonance imaging showed basal ganglia T2/fluid-attenuated inversion recovery hyperintensities without gadolinium enhancement. Cerebrospinal fluid testing showed slightly increased protein concentration and 8 cerebrospinal fluid-restricted oligoclonal bands. Serum and cerebrospinal fluid testing for neural autoantibodies showed immunoglobulin G immunoreactivity in a mouse tissue indirect immunofluorescence assay, predominantly staining the basal ganglia. The immunoglobulin G was subsequently identified to bind to phosphodiesterase 10A. The patient was diagnosed with paraneoplastic phosphodiesterase 10A-immunoglobulin G autoimmunity manifesting as hyperkinetic movement disorder triggered by immune checkpoint inhibitor treatment. Given the patient’s cancer remission, the immune checkpoint inhibitor treatment was discontinued. She was treated with high-dose intravenous corticosteroids, with improvement of her hyperkinetic movement disorder but persistence of some dystonic movements. Further treatment with oral prednisone did not produce further improvement. The patient was treated symptomatically with onabotulinumtoxinA injections and tetrabenazine, which ameliorated her dystonic movements. Three years after her cancer diagnosis, she was alive and in cancer remission with minimal residual movements. Immune checkpoint inhibitors are monoclonal antibodies targeting “stop signs” of the immune response, which lead to enhanced endogenous responses, including those against cancer. Autoimmune complications are consequences of the enhanced immunity and can affect all organs, including the nervous system.

scholarly journals Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers

JAMA Oncology ◽  
2020 ◽  
Vol 6 (7) ◽  
pp. 1068 ◽  
Author(s):  
Fausto Petrelli ◽  
Michele Ghidini ◽  
Antonio Ghidini ◽  
Gianluca Tomasello
Keyword(s):  
Microsatellite Instability ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Treatment

Factors associated with ocular adverse event after immune checkpoint inhibitor treatment

2020 ◽  
Vol 69 (12) ◽  
pp. 2441-2452 ◽  
Author(s):  
Yong Joon Kim ◽  
Jihei Sara Lee ◽  
Junwon Lee ◽  
Sung Chul Lee ◽  
Tae-im Kim ◽  
...  
Keyword(s):  
Adverse Event ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Factors Associated ◽  
Ocular Adverse Event ◽  
Inhibitor Treatment

Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?

2019 ◽  
Vol 71 (12) ◽  
pp. 1971-1973 ◽  
Author(s):  
Lenore M. Buckley ◽  
Maria E. Suarez‐Almazor
Keyword(s):  
Rheumatic Diseases ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Treatment
Sign in / Sign up

Export Citation Format

Share Document